News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Deals
Canterbury Park Ups Paragon Pharma Stake
November 18, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Canterbury Park Capital has acquired around 58.2 million additional common shares of Paragon Pharmacies Ltd. (TSX: PGN), for around C$23.2 million. It now holds over 68 million shares, or a 69.9% ownership position.
Twitter
LinkedIn
Facebook
Email
Print
Mergers & acquisitions
MORE ON THIS TOPIC
Mergers & acquisitions
Merck, AstraZeneca Cancer Collaborator Gets Swallowed Up by Sino Biopharm
July 16, 2025
·
1 min read
·
Tristan Manalac
Cancer
AbbVie Scoops Up Ichnos Glenmark’s Lead Myeloma Antibody for Nearly $2B
July 10, 2025
·
1 min read
·
Dan Samorodnitsky
Gene therapy
AstraZeneca Gains More Gene Therapy AAVs in JCR Deal Worth up to $825M
July 9, 2025
·
1 min read
·
Dan Samorodnitsky
M&A
Merck Makes Big Respiratory Play With $10B Acquisition of Verona
July 9, 2025
·
2 min read
·
Tristan Manalac